BUZZ-AtaiBeckley rises as depression drug moves toward late‑stage trials

Reuters03-10 18:21
BUZZ-AtaiBeckley rises as depression drug moves toward late‑stage trials

** Shares of  drugmaker AtaiBeckley ATAI.O rise 1.29% to $3.94 premarket

**  Co says its experimental depression drug BPL‑003 will enter late‑stage testing in Q2 2026 after positive FDA feedback

** Says BPL‑003 is aimed at treatment‑resistant depression, a severe form of the condition where common therapies do not work

**  Adds nasal‑spray drug showed rapid, lasting benefit in mid‑stage study, with effects seen in two days and lasting up to eight weeks

**  Two upcoming 12‑week trials, plus a year‑long extension, will test the drug against placebo - ATAI

**  Co reaffirms cash runway into early 2029 and reports progress on anxiety drug EMP‑01 and depression drug VLS‑01

** ATAI rose about three-fold in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment